PCI Biotech: Invitation to first half interim 2024 results presentation

Oslo, Norway, 23 August 2024 - PCI Biotech (OSE: PCIB) invites to a webcast presentation of the company's first half 2024 interim report on Wednesday 28 August 2024, 08:30am – 09:00am CEST (local time).

The presentation will be held as a live webcast available through The presentation will be held in Norwegian. There will be a Q&A session at the end of the presentation and it will be possible to post written questions through the webcast console. The interim report and presentation will be made available on and on the company's webpage, , from 07.00am CEST the same day.

For further information, please contact:

Ronny Skuggedal, CEO / CFO

Email:

Mobile:

About PCI Biotech         

PCI Biotech is a biopharmaceutical company focusing on developing and commercialising new technologies and novel therapies through its photochemical technology platform originating from world-leading research at the Oslo University Hospital. The technology platform is under development in two different areas. (1) Photochemical lysis (PCL), inducing selective light-triggered cell lysis, which may enhance yield and purity in viral vector manufacturing. (2) Photochemical internalisation (PCI), inducing light-triggered endosomal release, which may unlock the potential of a wide array of modalities.

For further information, please visit:                         

Contact information: PCI Biotech Holding ASA, Ullernchausséen 64, N-0379 Oslo                 



Forward-looking statements      

This announcement may contain forward-looking statements, which as such are not historical facts, but are based upon various assumptions, many of which are based, in turn, upon further assumptions. These assumptions are inherently subject to significant known and unknown risks, uncertainties and other important factors. Such risks, uncertainties, contingencies and other important factors could cause actual events to differ materially from the expectations expressed or implied in this announcement by such forward-looking statements. PCI Biotech disclaims any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.